GRAIL, Inc. (GRAL)
79.56
-2.98
(-3.62%)
USD |
NASDAQ |
Aug 26, 16:00
79.56
0.00 (0.00%)
After-Hours: 20:00
GRAIL EPS Diluted (Quarterly) : -2.557 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -2.557 |
| March 31, 2026 | -2.293 |
| December 31, 2025 | -2.435 |
| September 30, 2025 | -2.463 |
| June 30, 2025 | -3.185 |
| March 31, 2025 | -3.096 |
| December 31, 2024 | -2.864 |
| September 30, 2024 | -3.785 |
| Date | Value |
|---|---|
| June 30, 2024 | -51.06 |
| March 31, 2024 | -7.050 |
| December 31, 2023 | -6.039 |
| September 30, 2023 | -28.71 |
| June 30, 2023 | -6.217 |
| March 31, 2023 | -6.237 |
| September 30, 2020 | -0.58 |
| September 30, 2019 | -0.49 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -1.355 |
| Oncolytics Biotech, Inc. | -0.0788 |
| Sangamo Therapeutics, Inc. | -0.0796 |
| Sarepta Therapeutics, Inc. | -0.0464 |
| Anixa Biosciences, Inc. | -0.0749 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -110.25M |
| Revenue (Quarterly) | 44.69M |
| Total Expenses (Quarterly) | 154.93M |
| Enterprise Value | 2.916B |
| Gross Profit Margin (Quarterly) | -30.61% |
| Profit Margin (Quarterly) | -246.7% |
| Earnings Yield | -12.25% |
| Normalized Earnings Yield | -11.73 |